NIKKEI 225
27,346.88 +19.77 (+0.07%) HANG SENG
22,072.18 +229.85 (+1.05%) CRUDE OIL
76.54 -2.33 (-2.95%) GOLD FUTURES
1,937.20 -8.10 (-0.42%) DOW
33,728.71 -357.33 (-1.05%) BTC-GBP
18,689.39 -186.85 (-0.99%)
Adocia SA (0QAI.L)
| Previous close | 6.1158 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 29.583M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.3450 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Adocia Publishes Its Letter to Shareholders
LYON, France, January 30, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the publication of the January 2023 Letter to Shareholders.
- Business Wire
ADOCIA Announces Half Year Report on Adocia’s Liquidity Agreement With Kepler Capital Markets
LYON, France, January 23, 2023--Regulatory News: Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on December 31st, 2022:
- Business Wire
Number of Shares and Voting Rights of ADOCIA as of December 31st, 2022
LYON, France, January 16, 2023--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, releases its total number of outstanding shares as well as its voting rights as of December 31st, 2022.
